Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

FDM points to uptick in demand after tough 2024

(Sharecast News) - FDM Group saw a big drop in revenues and profits in 2024, but shares rose strongly on Wednesday after the tech consultancy pointed to an "encouraging" start to 2025. Chief executive Rod Flavell said the company had seen a "modest uptick in client demand across the majority of the regions in which we operate" so far this year. However, he said it was still too difficult to predict the timing of a sustained recovery in FDM's end-markets.

As reported in a pre-close update in January, full-year revenues were down 23% at £257.7m against a backdrop of "very challenging market conditions".

Clients assigned to clients by year-end were down 34% on the previous year at 2,578, with big declines across every geographic region.

Adjusted pre-tax profits were down 32% at £34m. However, reported profits were 49% lower at £28.1m, with the company incurring £4.9m in one-off costs to "better align" internal staff and undeployed consultants with current market dynamics.

FDM ended the year with £40.6m in cash, compared with £47.2m previously, and no debt. A final dividend of 12.5p per share was declared, taking the full-year payout to 22.5p. While down from the 36p payout in 2023, broker Shore Capital said the dividend "is slightly above the levels that the group's policy would have dictated".

Shares were up nearly 10% at 243p by 0904 GMT, rebounding strongly after a near-30% plunge since the start of 2025.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.